{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:11:08Z","timestamp":1782835868703,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ymgme.2012.01.019","type":"journal-article","created":{"date-parts":[[2012,1,31]],"date-time":"2012-01-31T04:59:02Z","timestamp":1327985942000},"page":"677-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibody-secreting plasma cells"],"prefix":"10.1016","volume":"105","author":[{"given":"Suhrad G.","family":"Banugaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trusha T.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Mackey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuti","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Amalfitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Charrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2012.01.019_bb0005","series-title":"Scriver's OMMBID the Online Metabolic & Molecular Bases of Inherited Disease","article-title":"Glycogen storage disease type II: Acid a-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2009"},{"key":"10.1016\/j.ymgme.2012.01.019_bb0010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2012.01.019_bb0020","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2012.01.019_bb0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0040","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0045","first-page":"135","volume":"14","author":"Messinger","year":"2012","journal-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease Genetics in medicine: official journal of the American College of Medical Genetics"},{"key":"10.1016\/j.ymgme.2012.01.019_bb0050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0055","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF02238520","article-title":"Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children","volume":"12","author":"Vogel","year":"1991","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0060","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1469-8749.1998.tb15399.x","article-title":"Assessment of gross motor skills of at-risk infants: predictive validity of the Alberta Infant Motor Scale","volume":"40","author":"Darrah","year":"1998","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0065","series-title":"Motor Assessment of the Developing Infant","author":"Piper","year":"1994"},{"key":"10.1016\/j.ymgme.2012.01.019_bb0070","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0075","doi-asserted-by":"crossref","first-page":"9169","DOI":"10.1073\/pnas.83.23.9169","article-title":"Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies","volume":"83","author":"Nilsson","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0080","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM198804143181503","article-title":"Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII","volume":"318","author":"Nilsson","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0085","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1542\/peds.100.6.e11","article-title":"Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease","volume":"100","author":"Brady","year":"1997","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2012.01.019_bb0090","first-page":"424","article-title":"Expression of the insulin-like growth factor-II\/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy","volume":"75","author":"Funk","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0095","first-page":"723","article-title":"Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues","volume":"23","author":"Wenk","year":"1991","journal-title":"Biochem. Int."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0100","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","article-title":"Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease","volume":"94","author":"McVie-Wylie","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0105","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","article-title":"Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model","volume":"152","author":"Joseph","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ymgme.2012.01.019_bb0110","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1542\/peds.2003-0988-L","article-title":"Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease","volume":"114","author":"Hunley","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2012.01.019_bb0115","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mus.22136","article-title":"Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease","volume":"44","author":"Banati","year":"2011","journal-title":"Muscle Nerve"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212000236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212000236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:20:25Z","timestamp":1761088825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719212000236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S1096719212000236"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2012.01.019","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibody-secreting plasma cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2012.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}